The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13
- PMID: 7795598
- DOI: 10.1093/hmg/4.3.429
The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13
Abstract
Oculopharyngeal muscular dystrophy (OPMD) is a late-onset autosomal dominant muscular dystrophy which presents typically after the age of 50 with progressive eyelid drooping and an increasing difficulty in swallowing. Though OPMD has a world-wide incidence, it is more common in the French Canadian population. We have identified a homogeneous group of families and studied 166 polymorphic markers as part of a genome search before establishing linkage to chromosome 14. We determined that the OPMD locus maps to a less than 5 cM region of chromosome 14q11.2-q13. The maximum two-point lod score in three French Canadian families of 14.73 (theta = 0.03) was obtained for an intronic cardiac beta myosin heavy chain gene (MYH7) marker. The regional localization for the OPMD locus raises the intriguing possibility that either the cardiac alpha or beta myosin heavy chain genes may play a role in this disease.
Similar articles
-
Genetic mapping and haplotype analysis of oculopharyngeal muscular dystrophy.Neuroreport. 1998 Apr 20;9(6):961-5. doi: 10.1097/00001756-199804200-00002. Neuroreport. 1998. PMID: 9601650
-
Confirmation of linkage of oculopharyngeal muscular dystrophy to chromosome 14q11.2-q13 in American families suggests the existence of a second causal mutation.Neuromuscul Disord. 1997 Oct;7 Suppl 1:S75-81. doi: 10.1016/s0960-8966(97)00087-4. Neuromuscul Disord. 1997. PMID: 9392021
-
Confirmation of linkage of oculopharyngeal muscular dystrophy to chromosome 14q11.2-q13.Ann Neurol. 1996 Nov;40(5):801-4. doi: 10.1002/ana.410400519. Ann Neurol. 1996. PMID: 8957024
-
Oculopharyngeal muscular dystrophy.Semin Neurol. 1999;19(1):59-66. doi: 10.1055/s-2008-1040826. Semin Neurol. 1999. PMID: 10711989 Review.
-
[Oculopharyngeal muscular dystrophy. A census of French families and genealogic study].Rev Neurol (Paris). 1990;146(6-7):425-9. Rev Neurol (Paris). 1990. PMID: 2204987 Review. French.
Cited by
-
Oculopharyngeal Muscular Dystrophy: A Case Report From Puerto Rico.Cureus. 2024 Jul 30;16(7):e65766. doi: 10.7759/cureus.65766. eCollection 2024 Jul. Cureus. 2024. PMID: 39082045 Free PMC article.
-
RNA-Based Therapy Utilizing Oculopharyngeal Muscular Dystrophy Transcript Knockdown and Replacement.Mol Ther Nucleic Acids. 2019 Apr 15;15:12-25. doi: 10.1016/j.omtn.2019.02.003. Epub 2019 Feb 15. Mol Ther Nucleic Acids. 2019. PMID: 30831428 Free PMC article.
-
Valproic acid is protective in cellular and worm models of oculopharyngeal muscular dystrophy.Neurology. 2018 Aug 7;91(6):e551-e561. doi: 10.1212/WNL.0000000000005942. Epub 2018 Jul 13. Neurology. 2018. PMID: 30006409 Free PMC article.
-
Genome engineering: a new approach to gene therapy for neuromuscular disorders.Nat Rev Neurol. 2017 Nov;13(11):647-661. doi: 10.1038/nrneurol.2017.126. Epub 2017 Sep 29. Nat Rev Neurol. 2017. PMID: 28960187 Review.
-
Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.Hum Mol Genet. 2017 Sep 1;26(17):3235-3252. doi: 10.1093/hmg/ddx206. Hum Mol Genet. 2017. PMID: 28575395 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
